Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00573144 · ClinicalTrials.gov registry record · Phase 2
Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction
A Phase 2 study of Acute Myocardial Infarction, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 2
- Study locations
NCT00573144 is a Phase 2 study of Acute Myocardial Infarction that has completed, run by Mayo Clinic. The registered enrollment target is 59 participants, below the 1,879-participant average among 19 other Acute Myocardial Infarction trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00573144, a Phase 2 study of Acute Myocardial Infarction, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the efficacy of intravenous human beta natriuretic peptide (BNP, Nesiritide) as compared to placebo to prevent adverse post acute myocardial infarction left ventricular remodeling.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nesiritide
Study Locations (2)
Florida
- Mayo Clinic - Jacksonvilee
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2006-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00573144
The ClinicalTrials.gov registry entry for NCT00573144 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,879-participant average among 19 other Acute Myocardial Infarction trials with a reported enrollment target (97% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myocardial Infarction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00573144 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00573144 about?
NCT00573144 is a clinical study titled "Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction". The purpose of this study is to determine the efficacy of intravenous human beta natriuretic peptide (BNP, Nesiritide) as compared to placebo to prevent adverse post acute myocardial infarction left ventricular remodeling.
What is the current status of trial NCT00573144?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2006-09. Estimated completion is 2013-04.
What conditions does trial NCT00573144 study?
This clinical trial studies the following conditions: Acute Myocardial Infarction.
What interventions are being tested in trial NCT00573144?
The interventions under investigation include: Placebo (DRUG), Nesiritide (DRUG).
Who is sponsoring clinical trial NCT00573144?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00573144 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
COMPLETED · Phase 2
-
A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
COMPLETED · Phase 2
-
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
RECRUITING · NA
-
Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock
RECRUITING
-
Abbott Vascular Medical Device Registry
RECRUITING
-
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.